 It uses a vaccine platform previously developed at OHSU to fight HIV and tuberculosis. Influenza pathogens are inserted into the common herpes virus, which infects most people with mild or no symptoms. It creates an immune response against the flu. The one-and-done shot could be available in 5 to 10 years.